Nifedipine

Q: Which cytochrome P450 isoenzyme metabolizes nifedipine in the liver?

The hepatic metabolism of nifedipine (Nifedipinum) is mediated by the CYP3A4 isoenzyme. This enzyme belongs to the cytochrome P450 system and is responsible for the biotransformation of a vast number of drugs. Nifedipine acts as a substrate for CYP3A4, meaning its presystemic metabolism, bioavailability, and final systemic concentration depend directly on the activity of this enzyme in hepatocytes and the intestinal wall.

Nifedipinum

For medical students2 min readUpdated 2026-10-10

Nifedipine is a dihydropyridine calcium channel blocker used in the management of hypertension and angina pectoris. The drug exerts a pronounced effect on the vasculature, decreasing afterload and improving myocardial perfusion.

Trade NamesAdalat, Procardia, Corinfar

Onset of Action15–20 minutes orally

Half-lifet1/2 is 2–4 hours

Primary TargetResistance and coronary vessels

Pharmacokinetic Profile

When administered orally, Nifedipinum demonstrates high absorption reaching approximately 90%. However, its bioavailability is about 50% due to significant first-pass hepatic metabolism.

Onset of therapeutic effect: 15–20 minutes.
Time to peak concentration ($C_{max}$): 1–2 hours (in plasma, 1–3 hours).
Duration of action for standard formulations: 6–8 hours.
Elimination half-life ($t_{1/2}$): 2–4 hours.
Metabolized in the liver and excreted primarily by the kidneys.

Mechanism of Antianginal Action

The main distinction between Nifedipinum and other calcium channel blockers is that dihydropyridines do not have a direct negative inotropic effect on the myocardium.

Their therapeutic effect is exerted exclusively on the vascular bed:

Acting on systemic resistance vessels, they reduce cardiac afterload.
Acting on coronary vessels, they increase myocardial oxygen delivery.

Indications and Formulations

The drug is indicated for the treatment of the following pathologies:

Vasospastic (Prinzmetal's) angina.
Chronic stable angina.
Essential hypertension.

Clinical Application of Different Formulations:

Short-acting formulations can be administered sublingually with an onset within 15 minutes, primarily used for acute blood pressure reduction.
Extended-release (sustained-release) formulations are taken twice daily and intended for chronic, maintenance management of hypertension.

Adverse Effects

Therapy with the drug may be accompanied by the following adverse reactions:

Excessive reduction in blood pressure (hypotension).
Reflex tachycardia, occurring in response to systemic vasodilation.
Peripheral ankle edema.

Mnemonic

Short-acting nifedipine under the tongue — hypertension gone (onset in 15 minutes).

Frequently asked questions

What side effects does nifedipine cause?

Nifedipine causes several adverse reactions predominantly related to its vasodilating properties. The main side effects include:

Hypotension — excessive blood pressure drop and mild orthostasis.
Reflex tachycardia — a compensatory sympathetic response to vasodilation.
Peripheral edema — a characteristic side effect presenting as ankle swelling.
Neurological symptoms — headache, dizziness, and fatigue.
Other effects — facial flushing and gingival hyperplasia.

What are the absolute contraindications to nifedipine?

Contraindications and cautions for nifedipine and other dihydropyridine calcium channel blockers include:

Cardiogenic shock;
Severe aortic stenosis;
Obstructive cardiomyopathy;
Severely low baseline blood pressure (use with caution).

Sublingual and intravenous administration are contraindicated during pregnancy and the postpartum period. Short-acting formulations should not be used for chronic, routine blood pressure control.

Which cytochrome P450 isoenzyme metabolizes nifedipine in the liver?

The hepatic metabolism of nifedipine (Nifedipinum) is mediated by the CYP3A4 isoenzyme. This enzyme belongs to the cytochrome P450 system and is responsible for the biotransformation of a vast number of drugs. Nifedipine acts as a substrate for CYP3A4, meaning its presystemic metabolism, bioavailability, and final systemic concentration depend directly on the activity of this enzyme in hepatocytes and the intestinal wall.

With which drug classes does nifedipine engage in clinically significant interactions?

Nifedipine interacts clinically with agents that alter CYP3A4 activity. Key drug classes include:

CYP3A4 inhibitors — azole antifungals, macrolide antibiotics, antiviral protease inhibitors (ritonavir), and non-dihydropyridine calcium channel blockers. They decrease nifedipine metabolism, increasing the risk of toxicity.
CYP3A4 inducers — anticonvulsants (carbamazepine, phenytoin, barbiturates), glucocorticoids, and rifampin. They accelerate metabolism, reducing drug efficacy.

Additionally, furanocoumarins in grapefruit juice cause irreversible intestinal enzyme inhibition.

Does nifedipine have a direct effect on the myocardium?

No. Unlike non-dihydropyridine calcium channel blockers, dihydropyridines act exclusively on blood vessels, decreasing afterload and dilating coronary arteries without directly suppressing cardiac contractility.

What is the primary clinical use of sublingual formulations?

Short-acting formulations are used sublingually for rapid blood pressure control because of their fast onset, which develops within 15 minutes.

Why are extended-release formulations preferred in modern practice?

Extended-release preparations provide more stable hemodynamics without sharp pulse surges and reflex sympathetic activation, while a less frequent dosing schedule improves patient adherence.

Go deeper

Classification of calcium channel blockers by chemical structure
Comparative pharmacokinetics of short-acting and extended-release dihydropyridines
Pathogenesis of reflex tachycardia induced by vasodilators
Hepatic metabolism pathways of nifedipine
Management of patients with concurrent hypertension and ischemic heart disease